Edgewise Pharma - EWTX Net earnings per share growth forecast for next year

Corporate company logo of Edgewise Therapeutics (EWTX)

Risk for Edgewise Therapeutics (EWTX) is linked to the search for new clinical trial leads. The trend in the company's EPS forecast indicates support, where -120.60 forms the current metric value. Stability is provided by massive investments in bioengineering and significant regulatory complexities in the development of neuromuscular drugs, which create a robust defensive barrier for the business.

Edgewise Pharma (EWTX): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Edgewise Pharma (EWTX)

Fundamental company analysis:Edgewise Therapeutics Inc, EWTX
Finished products of Edgewise Therapeutics Inc

The scale of ecosystem development for rare neuromuscular disease therapies at Edgewise Therapeutics (EWTX) is reflected in the forward net income trend. This metric aggregates analyst consensus forecasts for next year's earnings per share, allowing for an assessment of the company's ability to monetize innovations in muscle tissue protection and identifying the risks of inflated market expectations regarding business growth rates.

Competitors of Edgewise Therapeutics

Net earnings per share growth forecast for next year Jazz Pharmaceuticals|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Bio (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa Pharmaceuticals PLC CNTA|Dyne Pharma (DYN) - Expected net earnings per share growth next year|RAPP - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Alumis Inc.|ZVRA: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Contineum Pharma CTNM|Expected earnings per share growth for next year LRMR|Expected net earnings per share growth next year Capricor Therapeutics CAPR|Earnings growth forecast for next year TRDA|Expected earnings per share growth for next year Channel Therapeutics PTHS|Earnings growth forecast for next year MNOV (MediciNova)|Expected earnings per share trend next year SER|BTAI - Net earnings per share growth forecast for next year|promisneurosciences.com (PMN) - Expected earnings per share growth for next year|Apimeds (APUS) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year AEON|Net earnings per share growth forecast for next year NLS Pharma|Expected net earnings per share growth next year bionomics.com.au BNOX|Earnings growth forecast for next year HUGE|RETA (Reata Pharma) - Expected earnings per share trend next year